Zaleplon is a nonbenzodiazepine hypnotic agent and pyrazolo[1,5-a]pyrimidine derivative used for the short-term treatment of insomnia, specifically to help patients fall asleep. Our catalogue for this… Read more



![Chemical structure of (E)-N-(3-(3-Cyano-6-(3-(3-(N-ethylacetamido)phenyl)-3-oxoprop-1-en-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl)phenyl)-N-ethylacetamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F940951-61-1-E-N-3-3-Cyano-6-3-3-N-ethylacetamidophenyl-3-oxoprop-1-en-1-ylpyrazolo15-apyrimidin-7-ylphenyl-N-ethylacetamide.png&w=3840&q=75)





![Chemical structure of N-(3-(3-(4-Amino-2H-pyrazolo[3,4-d]pyrimidin-6-yl)pyrazolo[1,5-a]pyrimidin-7-yl)phenyl)-N-ethylacetamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F940951-52-0-N-3-3-4-Amino-2H-pyrazolo34-dpyrimidin-6-ylpyrazolo15-apyrimidin-7-ylphenyl-N-ethylacetamide.png&w=3840&q=75)
![Chemical structure of N-(3-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl)-N-ethylacetamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F478081-98-0-N-3-3-cyanopyrazolo15-apyrimidin-5-ylphenyl-N-ethylacetamide.png&w=3840&q=75)
![Chemical structure of N-(3-(3-Cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl)-N-methylacetamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F115932-13-3-N-3-3-Cyanopyrazolo15-apyrimidin-7-ylphenyl-N-methylacetamide.png&w=3840&q=75)


![Chemical structure of N-[3-(3-Dimethylaminoacryloyl)phenyl]-N-ethylacetamide-d5](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1104483-92-2-N-3-3-Dimethylaminoacryloylphenyl-N-ethylacetamide-d5.png&w=3840&q=75)
![Chemical structure of N-[3-[(2E)-3-(Dimethylamino)-1-oxo-2-propen-1-yl]phenyl]-formamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1227694-91-8-N-3-2E-3-Dimethylamino-1-oxo-2-propen-1-ylphenyl-formamide.png&w=3840&q=75)
![Chemical structure of N-[3-[(2E)-3-(Dimethylamino)-1-oxo-2-propen-1-yl]phenyl]-N-ethyl-formamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1227694-93-0-N-3-2E-3-Dimethylamino-1-oxo-2-propen-1-ylphenyl-N-ethyl-formamide.png&w=3840&q=75)
![Chemical structure of N-[3-[3-(Dimethylamino)-1-oxo-2-propenyl]phenyl]-N-ethylacetamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F96605-66-2-N-3-3-Dimethylamino-1-oxo-2-propenylphenyl-N-ethylacetamide.png&w=3840&q=75)


![Chemical structure of Zaleplon Related Compound A ((E)-N-(3-[3-(dimethylamino)acryloyl]phenyl)-N-ethylacetamide) (1724361)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FZaleplon-Related-Compound-A-E-N-3-3-dimethylaminoacryloylphenyl-N-ethylacetamide-1724361.png&w=3840&q=75)
![Chemical structure of Zaleplon Related Compound B (N-[3-(3-Cyanopyrazolo[1,5-alpha]pyrimidin-5-yl)phenyl]-N-ethylacetamid (1724372)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FZaleplon-Related-Compound-B-N-3-3-Cyanopyrazolo15-alphapyrimidin-5-ylphenyl-N-ethylacetamid-1724372.png&w=3840&q=75)
![Chemical structure of Zaleplon Related Compound C (7-[3-(N-ethylacetamido)phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide) (1724383)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F940951-54-2-Zaleplon-Related-Compound-C-7-3-N-ethylacetamidophenylpyrazolo15-apyrimidine-3-carboxamide-1724383.png&w=3840&q=75)

Zaleplon is a nonbenzodiazepine hypnotic agent and pyrazolo[1,5-a]pyrimidine derivative used for the short-term treatment of insomnia, specifically to help patients fall asleep. Our catalogue for this compound includes essential reference standards, impurities, and metabolites required for pharmaceutical analysis, method validation, and quality control. Researchers utilize these high-quality compounds, including pharmacopeial and non-pharmacopeial impurities like desethyl zaleplon and various oxo-analogs, for accurate impurity profiling and to establish rigorous safety standards. To support quantitative bioanalytical studies, we also provide stable isotope labelled compounds, such as zaleplon-d5, which serve as critical internal standards for mass spectrometry applications. These materials enable laboratories to ensure the consistency, efficacy, and regulatory compliance of their drug testing and development processes throughout the analytical lifecycle.